Protective Effects of Resveratrol and Quercetin Against MPP+ -induced Oxidative Stress Act by Modulating Markers of Apoptotic Death in Dopaminergic Neurons
Overview
Molecular Biology
Neurology
Affiliations
Reactive oxygen species produced by oxidative stress may participate in the apoptotic death of dopamine neurons distinctive of Parkinson's disease. Resveratrol, a red wine extract, and quercetin, found mainly in green tea, are two natural polyphenols, presenting antioxidant properties in a variety of cellular paradigms. The aim of this study was to evaluate the effect of resveratrol and quercetin on the apoptotic cascade induced by the administration of 1-methyl-4-phenylpyridinium ion (MPP(+)), a Parkinsonian toxin, provoking the selective degeneration of dopaminergic neurons. Our results show that a pre-treatment for 3 h with resveratrol or quercetin before MPP(+) administration could greatly reduce apoptotic neuronal PC12 death induced by MPP(+). We also demonstrated that resveratrol or quercetin modulates mRNA levels and protein expression of Bax, a pro-apoptotic gene, and Bcl-2, an anti-apoptotic gene. We then evaluated the release of cytochrome c and the nuclear translocation of the apoptosis-inducing factor (AIF). Altogether, our results indicate that resveratrol and quercetin diminish apoptotic neuronal cell death by acting on the expression of pro- and anti-apoptotic genes. These findings support the role of these natural polyphenols in preventive and/or complementary therapies for several human neurodegenerative diseases caused by oxidative stress and apoptosis.
Clemente-Suarez V, Martin-Rodriguez A, Curiel-Regueros A, Rubio-Zarapuz A, Tornero-Aguilera J Bioengineering (Basel). 2025; 12(2).
PMID: 40001727 PMC: 11851474. DOI: 10.3390/bioengineering12020208.
Boccardi V, Tagliafico L, Persia A, Page E, Ottaviani S, Cremonini A Nutrients. 2024; 16(20).
PMID: 39458427 PMC: 11510231. DOI: 10.3390/nu16203431.
Li H, Shao L, Chen X, Wang M, Qin Q, Yang Y Curr Med Sci. 2024; 44(4):854-863.
PMID: 39112916 DOI: 10.1007/s11596-024-2912-0.
Danisman B, Ercan Kelek S, Aslan M Psychiatry Clin Psychopharmacol. 2024; 33(2):147-155.
PMID: 38765928 PMC: 11082578. DOI: 10.5152/pcp.2023.23633.
Moshtaghion S, Caballano-Infantes E, Plaza Reyes A, Valdes-Sanchez L, Fernandez P, de la Cerda B Antioxidants (Basel). 2024; 13(2).
PMID: 38397799 PMC: 10886367. DOI: 10.3390/antiox13020201.